Rational drug design: A GAGE derived peptide kills tumor cells

Cancer Biology and Therapy

Volumn 9, Issue 10, 2010, Pages 825-831

  Kular, Rupinder K ^a   Yehiely, Fruma ^b   Deiss, Louis P ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Arginine rich peptides; Cancer therapy; GAGE; Tumor antigen

Indexed keywords

CANCER TESTIS ANTIGEN; PROTEIN GAGE; UNCLASSIFIED DRUG; CELL PENETRATING PEPTIDE; TUMOR PROTEIN; ARGININE; CANCER TESTIS ANTIGEN GAGE; FAS ANTIGEN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; PACLITAXEL;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL DEATH; CELL STRAIN HEK293; DRUG DESIGN; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; CELL SURVIVAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE INACTIVATION; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE; AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN BINDING; ANTIGEN EXPRESSION; CANCER THERAPY; CELL KILLING; CONTROLLED STUDY; GENE TARGETING; GENE TRANSLOCATION; IONIZING RADIATION; MAMMAL CELL; NONHUMAN; TUMOR CELL; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; HEK293 CELLS; HELA CELLS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 79960146645     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.10.11588     Document Type: Article

References (26)

1. Chen ME, Lin SH, Chung LW, Sikes RA. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 1998; 273:17618-25.
2. De Backer O, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 1999; 59:3157-65. (Pubitemid 29316016)
3. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995; 182:689-98.
4. Bazhin AV, Wiedemann N, Schnolzer M, Schadendorf D, Eichmuller SB. Expression of GAGE family proteins in malignant melanoma. Cancer Lett 2007; 251:258-67.
5. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, van de Rakt MW, Figdor CG, Adema GJ, et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 2007; 120:67-74.
6. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, et al. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 2006; 12:5442-7.
7. Oltra S, Martinez F, Orellana C, Grau E, Fernandez JM, Canete A, et al. Minimal residual disease in neuroblastoma: to GAGE or not to GAGE. Oncol Res 2004; 14:291-5.
8. Cilensek ZM, Yehiely F, Kular RK, Deiss LP. A member of the GAGE family of tumor antigens is an anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, Interferon-gamma, taxol and gamma-irradiation. Cancer Biol Ther 2002; 1:380-7.
9. Kular RK, Yehiely F, Kotlo KU, Cilensek ZM, Bedi R, Deiss LP. GAGE, an antiapoptotic protein binds and modulates the expression of nucleophosmin/B23 and interferon regulatory factor 1. J Interferon Cytokine Res 2009; 29:645-55.
10. Kondo T, Minamino N, Nagamura-Inoue T, Matsumoto M, Taniguchi T, Tanaka N. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 1997; 15:1275-81. (Pubitemid 27429742)
11. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996; 271:18188-93.
12. Kip1 induces cell migration. Nat Med 1998; 4:1449-52.
13. Asoh S, Ohsawa I, Mori T, Katsura K, Hiraide T, Katayama Y, et al. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci USA 2002; 99:17107-12.
14. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272:16010-7.
15. Futaki S. Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. Biopolymers 2006; 84:241-9.
16. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001; 276:5836-40.
17. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003; 278:585-90.
18. Futaki S, Nakase I, Tadokoro A, Takeuchi T, Jones AT. Arginine-rich peptides and their internalization mechanisms. Biochem Soc Trans 2007; 35:784-7. (Pubitemid 47310368)
19. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10:310-5.
20. Nakase I, Tadokoro A, Kawabata N, Takeuchi T, Katoh H, Hiramoto K, et al. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 2007; 46:492-501.
21. Khalil IA, Kogure K, Futaki S, Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 2006; 281:3544-51.
22. Sulochana KN, Ge R. Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des 2007; 13:2074-86.
23. Hoekstra R, de Vos FY, Eskens FA, de Vries EG, Uges DR, Knight R, et al. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. Eur J Cancer 2006; 42:467-72.
24. Hawkins RE, Daigneault L, Cowan R, Griffiths R, Panchal C, Armstrong A, et al. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clin Prostate Cancer 2005; 4:91-9.
25. Lamy S, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, Panchal C, et al. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: implication in tumor angiogenesis. Int J Cancer 2006; 118:2350-8.
26. Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis and optimization of pharmacokinetics and biological activities. J Med Chem 2005; 48:2838-46.